Design of new synthetic methodologies
- Design, synthesis and biological evaluation of new inhibitors of GPCR, TK and RTK (cancer), HIV (AIDS), HCV (Hepatitis C) and Myotonic Dystrophy.
- Design of new synthetic methodologies for heterocyclic systems based on microwaves.
MEMBER OF:
School of Engineering
Pharmaceutical Chemistry Group
The research focuses on two main areas: New Drugs in Biomedicine and Health Sciences and Flow Chemistry Processes.
LATEST PROJECTS
DisX4lymph (Interrupción de la interacción estroma-tumor en linfoma B utilizando inhibidores CXCR4 y degradadores IRAK4)
Diseño y síntesis de inhibidores alostéricos de CXCR4 y degradadores de IRAK4 como potencial tratamiento de linfoma de células B.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
PANCTKI (Nuevos inhibidores multidiana en terapia del cancer de pancreas)
Inhibidores de Tirosina Quinasas Duales en Cáncer de Páncreas: Cribado Virtual, Síntesis, Evaluación Biológica in vitro (2D y 3D) e in vivo.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
ProteoBlood (Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos)
Estudio de la homeostasis proteica en los dos subtipos de leucemia y linfoma.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
LINKED NEWS
News
New Therapies to Treat Leukaemia
08/07/2022
IQS has participated in the European project PROTEOblood, a cross-border project with the aim of studying and seeking new leukaemia and lymphoma treatments through understanding protein degradation and destruction cycles.
READ FULL NEW
News
Pharmacokinetic and Efficacy Studies
27/07/2021
IQS and the company Xenopat recently signed a collaboration agreement to carry out joint research projects concerning cancer and offer services to third parties by combining both entities' experience, including ADME-Tox, computational prediction, and in vivo efficacy studies, among other pharmacokinetic studies.
READ FULL NEW
